AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 71 min read$HIMS

Okupe Oluyemi sold $261K of HIMS

Okupe Oluyemi (Chief Financial Officer) sold 7,163 shares of Hims & Hers Health, Inc. (HIMS) at $36.49 ($0.26M total) on 2026-07-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Okupe Oluyemi
Published Jul 7, 2026, 8:20 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 7, 2026, 8:26 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$HIMS
Neutral
high confidence
Mentioned
$HIMS
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HIMSNeutralLow
01

Why it matters

The newest concrete fact is the CFO’s open-market sale details (shares, price, total value) and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

This is a routine insider-sale datapoint; it may marginally influence sentiment but does not introduce new business or financial guidance.

03

What to watch

Traders should check whether there are concurrent insider buys/sales, changes in trading volume, or any separate company disclosures around the same period; this filing alone is not a fundamental update.

Relevance 3/10Novelty 5/10Timing: today’s SEC Form 4 filing (filed 2026-07-07) for a 2026-07-06 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Hims & Hers Health, Inc.

Company-level read

Ticker impact

$HIMSNeutralHigh confidence
Context

CFO Okupe Oluyemi filed a Form 4 selling 7,163 shares of Hims & Hers at $36.4863 on 2026-07-06 under a 10b5-1 plan.

Expected impact

Likely minimal price impact; any reaction should fade unless accompanied by other company-specific catalysts.

Evidence & confidence

The disclosure is a scheduled open-market sale by an officer under a pre-arranged 10b5-1 plan, with no accompanying operational or guidance change stated.

Market effects

Sector

No direct sector read-through; this is an issuer-specific insider transaction.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a 10b5-1 plan, it may reflect diversification/compensation mechanics rather than bearish fundamentals.

Key entities

  • issuer
    Hims & Hers Health, Inc.

    Subject of the Form 4 insider transaction; CFO sold shares under a 10b5-1 plan.

  • insider
    Okupe Oluyemi

    Chief Financial Officer who reported the sale of 7,163 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

HIMS insider trading history →

Related articles

SEP 3
$HIMSHighAI 8/10

Hims & Hers Health (NYSE: HIMS) Faces Securities Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower -- HBSS

Hims & Hers Health (HIMS) faces a securities class action lawsuit following an FTC complaint alleging misconduct, including improper sharing of health data and deceptive billing practices. The FTC's lawsuit caused HIMS shares to drop 14.7% on July 29, 2026, erasing $970M in market cap. The lawsuit claims HIMS misled investors about its business practices and internal controls.

prnewswire.com2 min
SEP 2
$HIMSMed

HIMS Stock Kicks Off September In The Red: FDA’s GLP-1 Alert Steals The Spotlight From Australia Expansion

Hims & Hers Health (HIMS) stock fell 4% to $28.44 on Tuesday after the FDA issued a warning about unapproved GLP-1 weight-loss drugs. The company expanded into Australia but faces profitability pressures due to higher costs of approved GLP-1s. HIMS reported $753M revenue and an $86M net loss in Q2, raising its 2026 revenue forecast to $3.1B-$3.3B.

stocktwits.com2 min
AUG 31
$HIMSMed

Hims & Hers launches weight-loss drugs in Australia

Hims & Hers Health Inc (HIMS) launched GLP-1 weight-loss drugs and other treatments in Australia via its Pilot platform. The company acquired Eucalyptus, an Australian digital health platform, earlier in 2026. Hims aims to expand its services and targets $6.5 billion in revenue by 2030, though international growth has impacted gross margins. According to the company, international business has increased subscriptions and monthly revenue per subscriber by 21% year-over-year.

investing.com2 min
AUG 29
$HIMSMed

Dow, S&P 500, Nasdaq Futures Rise After Trump Says US-Iran War ‘Very Close To Over:’ Why HIMS, MSFT, RUM, NFLX, XNDU Are Trending After-Hours

U.S. stock futures rose after President Trump stated the U.S.-Iran war is 'very close to over.' The S&P 500 and Nasdaq Composite closed at record highs. HIMS surged 24% on FDA news, MSFT gained on AI sentiment, RUM hit a month high, NFLX rose ahead of earnings, and XNDU had its best day. Oil steadied near $91/barrel.

stocktwits.com2 min
AUG 28
$HIMSHighAI 8/10

Hims & Hers (HIMS) CEO Says the FTC Doesn’t Understand His Own Company

Hims & Hers (HIMS) CEO Andrew Dudum defended the company against an FTC lawsuit, citing its revenue growth and subscriber base. Q2 revenue rose 40% YoY to $753M, with a full-year forecast of $3.1B-$3.3B. However, margins fell to 64% from 76%, and free cash flow was negative $68M, raising concerns about profitability and legal risks.

yahoo.com2 min
AUG 28
$INTCHighAI 8/10

Why Are Nasdaq, Dow Futures Trading Mixed Premarket? INTC, SLS, SPCX, RKLB, ASTS, RIOT, FRMI Stocks Are In Focus

U.S. stock futures were mixed on Tuesday, with Nasdaq and Russell 2000 futures up 0.1%, Dow futures down 0.1%, and S&P 500 futures flat. Investors await July CPI data and geopolitical tensions impact sentiment. Key earnings reports include SMCI, CRWV, CAVA, LITE, and SLS. NVDA labeled AI data centers as investable assets, INTC upsized its share sale to $20B, and RIOT secured a $9.1B deal. RKLB shares fell despite a revenue beat, ASTS extended selloff, and SPCX faced lockup expiration pressures.

stocktwits.com3 min